Jones Trading Maintains Buy on Trevi Therapeutics, Raises Price Target to $28
Benzinga Newsdesk 2 months ago
NewsPrice TargetAnalyst Ratings
Jones Trading analyst Debanjana Chatterjee maintains Trevi Therapeutics (NASDAQ:TRVI) with a Buy and raises the price target from $24 to $28.
Jones Trading analyst Debanjana Chatterjee maintains Trevi Therapeutics (NASDAQ:TRVI) with a Buy and raises the price target from $24 to $28.